Firm Announcement
- AbbVie Inc. information criticism in opposition to Genmab within the U.S. District Courtroom for the Western District of Washington (Seattle)
- Genmab categorically refutes allegations and can vigorously defend the corporate
COPENHAGEN, Denmark; March 22, 2025 – Genmab A/S (Nasdaq: GMAB) introduced at the moment that
AbbVie Inc. (AbbVie) has filed a criticism within the U.S. District Courtroom for the Western District of Washington (Seattle) naming Genmab A/S; ProfoundBio US Co.; ProfoundBio (Suzhou) Co., Ltd.; and former AbbVie workers as defendants. AbbVie alleges that the defendants have misappropriated AbbVie’s alleged commerce secrets and techniques relating to the use of disaccharides to enhance the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs) in reference to rinatabart sesutecan (Rina-S™) and different ADC pipeline merchandise of ProfoundBio. Genmab acquired ProfoundBio in Might 2024.
AbbVie is searching for damages and broad injunctive reliefs. AbbVie’s alleged commerce secrets and techniques are associated to the use of disaccharides to enhance the hydrophilicity of drug-linkers in ADCs. AbbVie shouldn’t be asserting or implementing any patent rights in opposition to the defendants, and to Genmab’s data, AbbVie has not pursued any growth of merchandise incorporating their alleged commerce secrets and techniques.
Genmab categorically refutes these allegations and can vigorously defend the corporate in opposition to AbbVie’s claims.
Genmab notes that that is one more lawsuit amongst a number of latest lawsuits filed by AbbVie in opposition to rivals alleging misappropriation of its commerce secrets and techniques by former AbbVie workers.
Rina-S, to which this criticism relates, is a clinical-stage, FRα (folate receptor-alpha)-targeted, Topo1 ADC, in Part 3 growth for the remedy of ovarian most cancers and different FRα-expressing stable tumors. Rina-S is comprised of a proprietary antibody to FRα, a proprietary linker that mixes PEG (polyethylene glycol) with sorbitol, to obtain a differentiated hydrophilic protease cleavable linker that facilitates a homogenous drug to antibody-ratio (DAR) of 8 for the payload, exatecan, a second-generation topoisomerase I inhibitor.
Rina-S has the potential to tackle a broader affected person inhabitants in ovarian most cancers than is served by present customary of care, together with AbbVie’s Elahere®, with the potential to cowl the complete platinum-resistant ovarian most cancers (PROC) inhabitants regardless of FRα expression, primarily based on the information generated so far. Based mostly on the information from the continuing scientific trials, Genmab intends to broaden the event plans for Rina-S inside ovarian most cancers and different FRα-expressing stable tumors.
Genmab is an organization deeply rooted in science with a stable observe file within the discovery, growth and commercialization of differentiated antibody-based medicines, and can proceed to give attention to delivering worth to sufferers by way of novel antibody-based medicines.
Aside from pursuant to this firm announcement, Genmab doesn’t intend to remark or present extra data relating to the continuing litigation till a call is rendered on the deserves or different materials order is issued within the litigation or the litigation is in any other case concluded.
Whereas the lawsuit is pending, Genmab’s collaboration with AbbVie associated to epcoritamab will proceed unaffected. We stay totally dedicated to the epcoritamab broad scientific growth program and our commercialization efforts.
About Genmab
Genmab is a global biotechnology firm with a core objective of guiding its unstoppable group to attempt towards bettering the lives of sufferers with revolutionary and differentiated antibody therapeutics. For greater than 25 years, its passionate, revolutionary and collaborative group has invented next-generation antibody know-how platforms and leveraged translational, quantitative and knowledge sciences, leading to a proprietary pipeline together with bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s imaginative and prescient is to rework the lives of individuals with most cancers and different severe ailments with knock-your-socks-off (KYSO) antibody medicines®.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with worldwide presence throughout North America, Europe and Asia Pacific. For extra data, please go to Genmab.com and observe us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, International Communications & Company Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Firm Announcement incorporates ahead trying statements. The phrases “consider,” “count on,” “anticipate,” “intend” and “plan” and comparable expressions establish ahead trying statements. Precise outcomes or efficiency could differ materially from any future outcomes or efficiency expressed or implied by such statements. The essential components that might trigger our precise outcomes or efficiency to differ materially embrace, amongst others, dangers related to preclinical and scientific growth of merchandise, uncertainties associated to the end result and conduct of scientific trials together with unexpected issues of safety, uncertainties associated to product manufacturing, the dearth of market acceptance of our merchandise, our incapacity to handle progress, the aggressive surroundings in relation to our enterprise space and markets, our incapacity to appeal to and retain suitably certified personnel, the unenforceability or lack of safety of our patents and proprietary rights, {our relationships} with affiliated entities, modifications and developments in know-how which can render our merchandise or applied sciences out of date, and different components. For an extra dialogue of these dangers, please refer to the danger administration sections in Genmab’s most up-to-date monetary reviews, which can be found on www.genmab.com and the danger components included in Genmab’s most up-to-date Annual Report on Type 20-F and different filings with the U.S. Securities and Change Fee (SEC), which can be found at www.sec.gov. Genmab doesn’t undertake any obligation to replace or revise ahead trying statements on this Firm Announcement nor to affirm such statements to replicate subsequent occasions or circumstances after the date made or in relation to precise outcomes, until required by regulation.
Genmab A/S and/or its subsidiaries personal the next logos: Genmab®; the Y-shaped Genmab brand®; Genmab together with the Y-shaped Genmab brand®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
Firm Announcement no. 13
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark
- 220325_CA13_AbbVie Grievance
Source link
#Genmab #Vigorously #Defend #Alleged #Claims #Trade #Secret #Misappropriation #AbbVie
